Cannara Biotech Statistics

Total Valuation

Cannara Biotech has a market cap or net worth of 93.77 million. The enterprise value is 121.73 million.

Market Cap	93.77M
Enterprise Value	121.73M

Important Dates

The last earnings date was Monday, April 28, 2025.

Earnings Date	Apr 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.10%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	45.11M

Valuation Ratios

The trailing PE ratio is 19.79.

PE Ratio	19.79
Forward PE	n/a
PS Ratio	1.51
PB Ratio	1.45
P/TBV Ratio	1.45
P/FCF Ratio	13.38
P/OCF Ratio	8.35
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.49, with an EV/FCF ratio of 17.36.

EV / Earnings	25.69
EV / Sales	1.93
EV / EBITDA	11.49
EV / EBIT	20.13
EV / FCF	17.36

Financial Position

The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.54.

Current Ratio	2.01
Quick Ratio	0.64
Debt / Equity	0.54
Debt / EBITDA	3.34
Debt / FCF	4.99
Interest Coverage	1.71

Financial Efficiency

Return on equity (ROE) is 7.70% and return on invested capital (ROIC) is 3.88%.

Return on Equity (ROE)	7.70%
Return on Assets (ROA)	3.42%
Return on Invested Capital (ROIC)	3.88%
Return on Capital Employed (ROCE)	6.73%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.57
Inventory Turnover	1.42

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +71.89% in the last 52 weeks. The beta is 0.80, so Cannara Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	+71.89%
50-Day Moving Average	0.85
200-Day Moving Average	0.66
Relative Strength Index (RSI)	64.40
Average Volume (20 Days)	10,501

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cannara Biotech had revenue of 62.29 million and earned 4.74 million in profits. Earnings per share was 0.05.

Revenue	62.29M
Gross Profit	22.61M
Operating Income	5.98M
Pretax Income	3.86M
Net Income	4.74M
EBITDA	10.27M
EBIT	5.98M
Earnings Per Share (EPS)	0.05

Full Income Statement

Balance Sheet

The company has 7.32 million in cash and 34.95 million in debt, giving a net cash position of -27.63 million.

Cash & Cash Equivalents	7.32M
Total Debt	34.95M
Net Cash	-27.63M
Net Cash Per Share	n/a
Equity (Book Value)	64.65M
Book Value Per Share	0.72
Working Capital	26.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 11.23 million and capital expenditures -4.22 million, giving a free cash flow of 7.01 million.

Operating Cash Flow	11.23M
Capital Expenditures	-4.22M
Free Cash Flow	7.01M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 36.29%, with operating and profit margins of 9.59% and 7.60%.

Gross Margin	36.29%
Operating Margin	9.59%
Pretax Margin	6.20%
Profit Margin	7.60%
EBITDA Margin	16.49%
EBIT Margin	9.59%
FCF Margin	11.25%

Dividends & Yields

Cannara Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.10%
Shareholder Yield	-1.10%
Earnings Yield	5.05%
FCF Yield	7.48%

Stock Splits

The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Feb 13, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Cannara Biotech has an Altman Z-Score of 1.49. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.49
Piotroski F-Score	n/a